SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Sanofi to End Nurix’s SAR448272 Program After Phase 1 Trial

Nurix Therapeutics said Sanofi will discontinue the Phase 1 trial and terminate the program, ending potential payments tied to it.

NRIX

Related stories